iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
BI1335 HCV Protease in Phase 3 Now
  AASLD: Treatment with the 2nd generation HCV protease inhibitor BI 201335 results in high and consistent SVR rates - results from SILEN-C1 in treatment-naïve patients across different baseline factors - (11/08/11)
EASL: SVR4 and SVR12 with an interferon-free regimen of BI 201335 AND BI 207127, +/- ribavirin, in treatment-naïve patients with chronic genotype-1 HCV infection: Interim results of SOUND-C2 - (04/22/12)
EASL: The efficacy and safety of the interferon-free combination of BI 201335 and BI 207127 in genotype 1 HCV patients with cirrhosis: Interim analysis from SOUND-C2 - (04/20/12)
BI 207127 is a potent HCV RNA polymerase inhibitor during 5 days monotherapy in patients with chronic hepatitis C - (11/04/09)
Safety, pharmacokinetics and antiviral effect of BI 207127, a novel HCV RNA polymerase inhibitor, after 5 days' oral treatment in patients with chronic hepatitis C - (04/27/09)
Safety and antiviral activity of BI 201335, a new HCV NS3 protease ... www.natap.org/2008/AASLD/AASLD_13.htm Nov 1, 2008 - BI 201335 induced a pronounced virologic response typically within 2 to 4 days of initiation of monotherapy (from Jules: median maximal -4.


  iconpaperstack View Older Articles   Back to Top   www.natap.org